NCT00680108View on ClinicalTrials.gov

A Study to Determine the Safety and Tolerability of Escalating Doses of INS365 Ophthalmic Solution

PHASE2CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

September 30, 1999

Primary Completion Date

May 31, 2000

Study Completion Date

May 31, 2000

Conditions
Dry Eye Disease
Interventions
DRUG

diquafosol tetrasodium (INS365) ophthalmic solution

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00680108 - A Study to Determine the Safety and Tolerability of Escalating Doses of INS365 Ophthalmic Solution | Biotech Hunter | Biotech Hunter